Skip to main content
Article thumbnail
Location of Repository

Circulating cell death products predict clinical outcome of colorectal cancer patients

By Pim J Koelink, Cornelis BHW Lamers, Daan W Hommes and Hein W Verspaget
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2666761
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2003). A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis
    2. (2002). A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs
    3. (2004). Apoptotic markers in cancer. Clin Biochem
    4. (2001). Cheung AN: Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: assessment by the caspase-related M30 CytoDeath antibody. Histopathology
    5. (2004). De Vries EG, Kleibeuker JH: Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas. Histopathology
    6. (2003). De Vries EG, Kleibeuker JH: Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol
    7. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin
    8. (2007). Dive C: Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother Pharmacol
    9. (2006). Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.
    10. (2007). et al.: Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res
    11. (2008). Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol
    12. (2007). Hypoxia-inducible factors, stem cells, and cancer. Cell
    13. (2004). Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol
    14. (1999). Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis.
    15. (1994). RG: Oncogene activation of human keratin 18 transcription via the Ras signal transduction pathway.
    16. (1951). RJ: Protein measurement with the Folin phenol reagent.
    17. (2003). S: Measurement of an apoptotic product in the sera of breast cancer patients.
    18. (2004). Seol DW: Hypoxia inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by blocking Bax translocation. Cancer Res
    19. (2007). The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.